Sarah E. Pierce
Research Subjects
Sarah E. Pierce has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- William James Greenleaf
Department of Genetics, Stanford School of Medicine, Stanford, USA
41 shared publications - Monte M. Winslow
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
38 shared publications - Samuel H. Kim
Cancer Biology Program, Stanford University, Stanford, CA, USA
35 shared publications - Anne Kathrin Voss
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3050, Australia
34 shared publications - Christian A. Kunder
Department of Pathology, Stanford University School of Medicine, Stanford, California
34 shared publications - Colin Detrick
Department of Genetics, Stanford University School of Medicine, Stanford, California
34 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (7) , 1-14
Efficient prime editing in vivo and in vitro using lipid nanoparticles
Prime editing is a versatile clinical genome editing method that enables precise substitutions, small insertions and deletions at specified locations in the genomes of living systems including human cells. Although non-viral lipid nanoparticle (LNP) delivery of RNA in vivo has become a preferred method for gene editing in animals and patients, its application to complex, three-component prime editing systems has yielded low editing efficiencies. Here we developed a systematic prime editing LNP (PE-LNP) optimization platform that addresses key bottlenecks in cargo design that limit editing efficiency. This generalizable workflow yielded PE-LNPs that can achieve 49% average in vivo prime editing in the bulk mouse liver with a single dose of 2 mg kg −1 . We applied our workflow to the correction of PAH R408W, a cause of phenylketonuria, in a mouse model and achieved prime editing efficiencies and serum phenylalanine levels anticipated to be curative. We also show that PE-LNPs minimize off-target editing compared with DNA delivery methods, induce only transient elevation of liver enzymes and can be dosed repeatedly to improve editing efficiencies. These PE-LNP systems provide an attractive alternative to viral delivery by offering transient expression that minimizes off-target editing, no observed long-term toxicity and high levels of non-viral in vivo liver prime editing.
- 15 June 2026
- Published by Springer Nature in Nature Nanotechnology
- Vol. 21 (7) , 1-14
Open AccessEfficient prime editing in vivo and in vitro using lipid nanoparticles
Prime editing is a versatile clinical genome editing method that enables precise substitutions, small insertions and deletions at specified locations in the genomes of living systems including human cells. Although non-viral lipid nanoparticle (LNP) delivery of RNA in vivo has become a preferred method for gene editing in animals and patients, its application to complex, three-component prime editing systems has yielded low editing efficiencies. Here we developed a systematic prime editing LNP (PE-LNP) optimization platform that addresses key bottlenecks in cargo design that limit editing efficiency. This generalizable workflow yielded PE-LNPs that can achieve 49% average in vivo prime editing in the bulk mouse liver with a single dose of 2 mg kg −1 . We applied our workflow to the correction of PAH R408W, a cause of phenylketonuria, in a mouse model and achieved prime editing efficiencies and serum phenylalanine levels anticipated to be curative. We also show that PE-LNPs minimize off-target editing compared with DNA delivery methods, induce only transient elevation of liver enzymes and can be dosed repeatedly to improve editing efficiencies. These PE-LNP systems provide an attractive alternative to viral delivery by offering transient expression that minimizes off-target editing, no observed long-term toxicity and high levels of non-viral in vivo liver prime editing.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Supplemental Figure 1. Tuba-seqUltra enables scalable and cost-effective in vivo functional genomics with clonal resolution in autochthonous cancer models. Supplemental Fig 2. Schematic of Tuba-seqUltra sample processing, high-throughput barcode-sgRNA sequencing data analysis, and tumor metric calculation. Supplemental Figure 3. Tuba-seqUltra enables the quantification of multiple tumorigenesis metrics from millions of clonal autochthonous lung tumors. Supplemental Figure 4. Tumor-suppressive and tumor-dependency epigenomic regulators in lung tumorigenesis. Supplemental Figure 5. High-throughput MYST and COMPASS saturation analysis in vivo identifies additional epigenomic regulators driving lung tumorigenesis. Supplemental Figure 6. Tumor-suppressive and tumor-dependency genes in the Lenti-U6BCsgRNASaturation/Cre library.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Supplemental Figure 1. Tuba-seqUltra enables scalable and cost-effective in vivo functional genomics with clonal resolution in autochthonous cancer models. Supplemental Fig 2. Schematic of Tuba-seqUltra sample processing, high-throughput barcode-sgRNA sequencing data analysis, and tumor metric calculation. Supplemental Figure 3. Tuba-seqUltra enables the quantification of multiple tumorigenesis metrics from millions of clonal autochthonous lung tumors. Supplemental Figure 4. Tumor-suppressive and tumor-dependency epigenomic regulators in lung tumorigenesis. Supplemental Figure 5. High-throughput MYST and COMPASS saturation analysis in vivo identifies additional epigenomic regulators driving lung tumorigenesis. Supplemental Figure 6. Tumor-suppressive and tumor-dependency genes in the Lenti-U6BCsgRNASaturation/Cre library.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
GO enrichment of tumor suppressive epigenomic regulators
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
GO enrichment of tumor suppressive epigenomic regulators
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Genes included in the Lenti-U6BCsgRNAEpigenomics/Cre library
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Genes included in the Lenti-U6BCsgRNAEpigenomics/Cre library
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S18 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Motif analysis of overlapping regions with decreased chromatin accessibility
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S18 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Motif analysis of overlapping regions with decreased chromatin accessibility
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S8 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
SgRNA level data from the Lenti-U6BCsgRNASaturation/Cre library in KTC mice
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
SgRNA level data from the Lenti-U6BCsgRNASaturation/Cre library in KTC mice
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S17 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Differential chromatin accessibility in sgKat7 relative to sgSafe-transduced neoplastic cells using consensus regions
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S17 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Differential chromatin accessibility in sgKat7 relative to sgSafe-transduced neoplastic cells using consensus regions
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S19 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Motif analysis of overlapping regions with increased chromatin accessibility
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S19 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Motif analysis of overlapping regions with increased chromatin accessibility
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S7-S20 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Supplemental Figure 7. Inactivation of the HBO1 complex genes reduces H3K14ac and H4K12ac levels in lung tumors and worsens tumor grade. Supplemental Figure 8. Tumor-suppressive genes in the MLL1 complex are mutated, and genetic alterations in the HBO1JADE2-ING5 and MLL1 complexes are associated with survival in human lung adenocarcinoma. Supplemental Figure 9. H3K14ac is reduced in a subset of human lung adenocarcinomas. Supplemental Figure 10. HBO1 complex target histone modifications and H3K36me3 are disrupted in human lung adenocarcinoma. Supplemental Figure 11. Inactivation of HBO1 or MLL1 complex genes results in highly correlated chromatin accessibility landscapes. Supplemental Figure 12. Inactivating genes in the HBO1 or MLL1 complex alters chromatin accessibility at shared regions enriched for lineage transcription factor motifs and at known tumor suppressor genes. Supplemental Figure 13. Chromatin binding profiles of the HBO1 and MLL1 complexes and their target histone modifications across the genome. Supplemental Figure 14. HBO1 complex catalytic activity functions in suppressing lung cancer cell proliferation. Supplemental Figure 15. Inactivation of HBO1 or MLL1 complex genes alters transcriptional states in lung tumor cells. Supplemental Figure 16. Inactivation of HBO1 or MLL1 complex genes suppresses tumor suppressor gene expression and disrupts lineage fidelity. Supplemental Figure 17. Transcriptional impact of Kat7 deletion in normal lung AT2 cells. Supplemental Figure 18. Cancer dependency score correlation and tumor growth metrics from Lenti-U6BCsgRNAEpistasis/Cre library. Supplemental Figure 19. Kat7 is synthetic lethal with Stag2-Cohesin complex. Supplemental Figure 20. Tumor sizes at different percentiles upon perturbing the HBO1JADE2-ING5 or MLL1 complex in multiple genetic driver contexts.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S7-S20 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
Supplemental Figure 7. Inactivation of the HBO1 complex genes reduces H3K14ac and H4K12ac levels in lung tumors and worsens tumor grade. Supplemental Figure 8. Tumor-suppressive genes in the MLL1 complex are mutated, and genetic alterations in the HBO1JADE2-ING5 and MLL1 complexes are associated with survival in human lung adenocarcinoma. Supplemental Figure 9. H3K14ac is reduced in a subset of human lung adenocarcinomas. Supplemental Figure 10. HBO1 complex target histone modifications and H3K36me3 are disrupted in human lung adenocarcinoma. Supplemental Figure 11. Inactivation of HBO1 or MLL1 complex genes results in highly correlated chromatin accessibility landscapes. Supplemental Figure 12. Inactivating genes in the HBO1 or MLL1 complex alters chromatin accessibility at shared regions enriched for lineage transcription factor motifs and at known tumor suppressor genes. Supplemental Figure 13. Chromatin binding profiles of the HBO1 and MLL1 complexes and their target histone modifications across the genome. Supplemental Figure 14. HBO1 complex catalytic activity functions in suppressing lung cancer cell proliferation. Supplemental Figure 15. Inactivation of HBO1 or MLL1 complex genes alters transcriptional states in lung tumor cells. Supplemental Figure 16. Inactivation of HBO1 or MLL1 complex genes suppresses tumor suppressor gene expression and disrupts lineage fidelity. Supplemental Figure 17. Transcriptional impact of Kat7 deletion in normal lung AT2 cells. Supplemental Figure 18. Cancer dependency score correlation and tumor growth metrics from Lenti-U6BCsgRNAEpistasis/Cre library. Supplemental Figure 19. Kat7 is synthetic lethal with Stag2-Cohesin complex. Supplemental Figure 20. Tumor sizes at different percentiles upon perturbing the HBO1JADE2-ING5 or MLL1 complex in multiple genetic driver contexts.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Table S20 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
DGE of KP787 cell line treated with WM3835 relative to DMSO
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S20 from Functional Mapping of Epigenomic Regulators Uncovers Coordinated Tumor Suppression by the HBO1 and MLL1 Complexes
DGE of KP787 cell line treated with WM3835 relative to DMSO